USPTO Patent Grant: Botulinum Toxin for Infertility Treatment
Summary
The USPTO has granted a patent (US12582705B2) to CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a composition comprising botulinum toxin or a salt thereof. This composition is intended to increase endometrial blood flow and improve implantation potential, potentially treating subfertility or infertility.
What changed
The United States Patent and Trademark Office (USPTO) has issued patent US12582705B2 for a novel composition containing botulinum toxin or its salt. The patent, assigned to CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, claims the use of this composition to increase endometrial blood flow and enhance embryonic implantation potential, offering a potential treatment for subfertility and infertility, particularly for patients with recurrent implantation failures.
This patent grant is primarily informational for the pharmaceutical and healthcare sectors. While it does not impose new regulatory obligations, it signifies a new intellectual property development in the therapeutic use of botulinum toxin. Companies operating in the fertility treatment or pharmaceutical manufacturing space should be aware of this patented technology, as it may impact future product development and market exclusivity in this therapeutic area.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Composition comprising botulinum toxin or salt thereof for increasing endometrial blood flow rate
Grant US12582705B2 Kind: B2 Mar 24, 2026
Assignee
CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors
Youn Jung Kang, Hwa Seon Koo, Jung Jae Ko
Abstract
A composition may increase a rate of endometrial blood flow and a composition for increasing implantation potential, including botulinum toxin or a salt thereof, and a pharmaceutical composition may preventing or treating subfertility or infertility, including botulinum toxin or a pharmaceutically acceptable salt thereof. Such compositions can increase a rate of endometrial blood flow and improve embryonic implantation potential just by being applied to the endometrium, and thus may be helpful to patients with subfertility or infertility, especially those who have repetitive failures in embryonic implantation. Since the compositions include botulinum toxin which is a substance that has been widely applied to the human body for cosmetic purposes, studies on human toxicity may have a shortened period, and thus the disclosure is very useful in economical and industrial aspects.
CPC Classifications
A61K 38/4893 A61K 38/48 A61P 15/08
Filing Date
2020-04-28
Application No.
17773391
Claims
15
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.